J. Biol. Chem., Vol. 259, Issue 15, 9575-9579, Aug, 1984

Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase

PA Furman, MH St. Clair and T Spector

The triphosphate form of 9-[(2-hydroxyethoxy)-methyl]guanine (acyclovir), ACVTP, inactivates the herpes simplex virus type 1 DNA polymerase. ACVTP does not innately inactivate resting polymerase, but becomes an inactivator only while being processed as an alternative substrate. Pseudo first-order rates of inactivation were measured at varying concentrations of ACVTP and fixed concentrations of the natural substrate, deoxyguanosine triphosphate. These studies indicated that a reversible enzyme-ACVTP (Michaelis-type) complex is formed at the active site prior to inactivation. The formation of this complex was competitively retarded by deoxyguanosine triphosphate. An apparent dissociation constant (KD) of 3.6 +/- 0.2 (S.D.) nM was determined for ACVTP from this reversible complex. A second method for the estimation of the KD which used the extrapolated initial velocities produced a value of 5.9 +/- 0.4 (S.D.) nM. The rate of conversion of the reversible complex to the inactivated complex, at saturating ACVTP, was calculated to be 0.24 min-1. No reactivation of enzyme activity was detected following isolation of the inactivated complex by rapid desalting on Sephadex G-25. Under these conditions, an overall reactivation rate of 1.5 X 10(-5) min-1 could have been easily detected. Therefore, the overall inhibition constant must have been less than 3 pM. In contrast, when host DNA polymerase alpha was incubated with 14 microM ACVTP, only 60% inhibition of enzyme activity was observed, but inactivation was not detected. These data indicate that ACVTP functions as a suicide inactivator of the herpes simplex virus type 1 DNA polymerase, and is only a weak reversible inhibitor of DNA polymerase alpha.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. W. Hanes, Y. Zhu, D. S. Parris, and K. A. Johnson Enzymatic Therapeutic Index of Acyclovir: VIRAL VERSUS HUMAN POLYMERASE {gamma} SPECIFICITY J. Biol. Chem., August 24, 2007; 282(34): 25159 - 25167. [Abstract] [Full Text] [PDF]

				A Chaudhuri and P G E Kennedy Diagnosis and treatment of viral encephalitis Postgrad. Med. J., October 1, 2002; 78(924): 575 - 583. [Abstract] [Full Text] [PDF]

				M. S. Kokoris and M. E. Black Characterization of Herpes Simplex Virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity Protein Sci., September 1, 2002; 11(9): 2267 - 2272. [Abstract] [Full Text] [PDF]

				H. H. Balfour Antiviral Drugs N. Engl. J. Med., April 22, 1999; 340(16): 1255 - 1268. [Full Text] [PDF]

				G. Elion The purine path to chemotherapy Science, April 7, 1989; 244(4900): 41 - 47. [Abstract] [PDF]